Physician profile
Patrick N Larrazabal
NPI 1518923275
$2,793.20
in general payments reported to CMS, 2019-2025
21 companies · $651 in 2025
The $651 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103 · 2020: $265 · 2021: $300 · 2022: $497 · 2023: $414 · 2024: $563 · 2025: $651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,627.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $453.56 | 2020-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $439.01 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $339.27 | 2019-2025 | Airsupra, Farxiga |
| Abbvie INC. | $261.82 | 2021-2025 | |
| Amgen INC. | $256.66 | 2019-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $211.64 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $101.78 | 2021-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.65 | 2021-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.86 | 2021-2025 | Xifaxan |
| Pfizer INC. | $94.82 | 2020-2025 | |
| Exact Sciences Corporation | $82.59 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $78.72 | 2019-2022 | |
| Renalytix Ai, INC. | $65.32 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Astellas Pharma US INC | $65.00 | 2019 | |
| Amarin Pharma, INC. | $36.48 | 2020-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $27.20 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $20.54 | 2021 | |
| Tolmar, INC. | $14.68 | 2025 | Jatenzo |
| Janssen Pharmaceuticals, INC | $14.36 | 2022 | |
| Allergan, INC. | $14.15 | 2020 | |
| Eisai INC. | $14.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Larrazabal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.